These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38081767)

  • 1. Neutrophil-lymphocyte ratio in patients with idiopathic pleuroparenchymal fibroelastosis.
    Suzuki Y; Kono M; Hasegawa H; Hashimoto D; Yokomura K; Imokawa S; Inoue Y; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38081767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume.
    Fukada A; Suzuki Y; Mori K; Kono M; Hasegawa H; Hashimoto D; Yokomura K; Imokawa S; Tanaka Y; Inoue Y; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Fujino Y; Nakamura H; Suda T
    Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 35798359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-lymphocyte ratio being associated with mortality risk in patients receiving antifibrotic therapy.
    Takuma S; Suzuki Y; Kono M; Hasegawa H; Hashimoto D; Yokomura K; Mori K; Shimizu M; Inoue Y; Yasui H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Respir Med; 2024 Mar; 223():107542. PubMed ID: 38331228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis.
    Kono M; Fujita Y; Takeda K; Miyashita K; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Enomoto N; Nakamura Y; Suda T; Nakamura H
    Respir Med; 2019; 154():122-126. PubMed ID: 31238182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of malnutrition-related risk in patients with idiopathic pleuroparenchymal fibroelastosis.
    Suzuki Y; Fukada A; Mori K; Kono M; Hasegawa H; Hashimoto D; Yokomura K; Imokawa S; Inoue Y; Yasui H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura H; Suda T
    ERJ Open Res; 2023 May; 9(3):. PubMed ID: 37228291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of idiopathic pleuroparenchymal fibroelastosis with progressive phenotype showing a decline in forced vital capacity.
    Kono M; Tsunoda T; Ikeda S; Yagi S; Hirama R; Watanuki M; Oshima Y; Tsutsumi A; Miwa H; Miki Y; Hashimoto D; Suda T; Nakamura H
    Respir Investig; 2023 Mar; 61(2):210-219. PubMed ID: 36773509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal.
    Watanabe K; Ishii H; Kiyomi F; Terasaki Y; Hebisawa A; Kawabata Y; Johkoh T; Sakai F; Kondoh Y; Inoue Y; Azuma A; Suda T; Ogura T; Inase N; Homma S;
    Respir Investig; 2019 Jul; 57(4):312-320. PubMed ID: 30981683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of lung elastic fibers in idiopathic pleuroparenchymal fibroelastosis (IPPFE): comparison of clinical, radiological, and pathological findings with those of idiopathic pulmonary fibrosis (IPF).
    Enomoto N; Kusagaya H; Oyama Y; Kono M; Kaida Y; Kuroishi S; Hashimoto D; Fujisawa T; Yokomura K; Inui N; Nakamura Y; Suda T
    BMC Pulm Med; 2014 May; 14():91. PubMed ID: 24886550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage.
    Shioya M; Otsuka M; Yamada G; Umeda Y; Ikeda K; Nishikiori H; Kuronuma K; Chiba H; Takahashi H
    Can Respir J; 2018; 2018():6043053. PubMed ID: 30186537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients.
    Kusagaya H; Nakamura Y; Kono M; Kaida Y; Kuroishi S; Enomoto N; Fujisawa T; Koshimizu N; Yokomura K; Inui N; Suda T; Colby TV; Chida K
    BMC Pulm Med; 2012 Dec; 12():72. PubMed ID: 23216996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia.
    Yamagata A; Arita M; Tachibana H; Tokioka F; Sugimoto C; Sumikawa H; Tanaka T; Yasui H; Fujisawa T; Nakamura Y; Suda T; Ishida T
    Respir Res; 2021 Apr; 22(1):115. PubMed ID: 33879137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of lung transplantation for idiopathic pleuroparenchymal fibroelastosis.
    Shiiya H; Nakajima J; Date H; Chen-Yoshikawa TF; Tanizawa K; Handa T; Oto T; Otani S; Shiotani T; Okada Y; Matsuda Y; Shiraishi T; Moroga T; Minami M; Funaki S; Chida M; Yoshino I; Hatachi G; Uemura Y; Sato M
    Surg Today; 2021 Aug; 51(8):1276-1284. PubMed ID: 33576927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis.
    Suzuki Y; Fujisawa T; Sumikawa H; Tanaka T; Sugimoto C; Kono M; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    Respir Med; 2020 Sep; 171():106078. PubMed ID: 32917352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.
    Kinoshita Y; Ishii H; Nabeshima K; Watanabe K
    Histol Histopathol; 2021 Mar; 36(3):291-303. PubMed ID: 33315234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis.
    Kinoshita Y; Miyamura T; Ikeda T; Ueda Y; Yoshida Y; Kushima H; Ishii H
    Respir Investig; 2022 Jul; 60(4):562-569. PubMed ID: 35398003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usual Interstitial Pneumonia Pattern in the Lower Lung Lobes as a Prognostic Factor in Idiopathic Pleuroparenchymal Fibroelastosis.
    Kato M; Sasaki S; Kurokawa K; Nakamura T; Yamada T; Sasano H; Arano N; Komura M; Ihara H; Nagashima O; Shiota S; Takahashi F; Takahashi K
    Respiration; 2019; 97(4):319-328. PubMed ID: 30522096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum latent transforming growth factor-β binding protein 4 as a novel biomarker for idiopathic pleuroparenchymal fibroelastosis.
    Kinoshita Y; Ikeda T; Kushima H; Fujita M; Nakamura T; Nabeshima K; Ishii H
    Respir Med; 2020 Sep; 171():106077. PubMed ID: 32658840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia.
    Sugino K; Ono H; Shimizu H; Kurosawa T; Matsumoto K; Ando M; Mori K; Tsuboi E; Homma S; Kishi K
    ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33681342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Mass Index and arterial blood oxygenation as prognostic factors in patients with idiopathic pleuroparenchymal fibroelastosis.
    Hayashi H; Nei T; Abe S; Saito Y; Kokuho N; Atsumi K; Fujita K; Saito T; Tanaka T; Gemma A; Azuma A
    Sarcoidosis Vasc Diffuse Lung Dis; 2017; 34(1):35-40. PubMed ID: 32476820
    [No Abstract]   [Full Text] [Related]  

  • 20. Idiopathic pleuroparenchymal fibroelastosis, a new idiopathic interstitial pneumonia: A case report.
    Hurtado EJ; González ML; Soto Mdel M; Rueda FJ; Nadal FJ; Cantero AR
    Chron Respir Dis; 2016 Aug; 13(3):312-6. PubMed ID: 26810762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.